BioNTech SE
An der Goldgrube 12
D-55131 Mainz
Germany
February 3, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: Paul Fischer
| Re: | BioNTech SE |
Registration Statement on FormF-1
Filed February 3, 2020
FileNo. 333-236225
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), BioNTech SE (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on FormF-1 (the “Registration Statement”) be accelerated by the U.S. Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on February 5, 2020, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.
We respectfully request that we be notified of such effectiveness by a telephone call to Eric W. Blanchard of Covington & Burling LLP at (212)841-1111 and that such effectiveness also be confirmed in writing.
| Respectfully, | ||
| BioNTech SE | ||
| By: | /s/ Prof. Ugur Sahin, M.D. | |
| Name: | Prof. Ugur Sahin, M.D. | |
| Title: | Chief Executive Officer | |
cc: Eric W. Blanchard, Covington & Burling LLP
